Regulacje i polityka gospodarcza · 17/10/2007

National Institutes of Health to Grant Exclusive License for Cancer Treatment Compound

The National Institutes of Health is considering granting an exclusive license to Emiliem, Inc. to use a novel mTOR kinase inhibitor, LY303511, for the treatment of certain types of cancer and proliferative disorders, excluding stenosis and restenosis.

Source: Federal Register — All DocumentsOpen original release →

Find a company or service

Business Communicator helps companies present their offer, publish updates and connect directly.

Create a company profile Explore businesses on Business Maps →

LATEST SIGNALS

Regulacje i polityka gospodarcza · 10/14/2026

Department of War Requests Comments on Proposed Manual for Courts-Martial Amendments

The Department of War (DoW) is seeking comments on proposed changes to the Manual for Courts-Martial (MCM) and has announced a public meeting to receive comments on the changes.

Read summary →